ZBH Surges 13.5% as Hips and Guidance Lift Zimmer Biomet
Zimmer Biomet stock jumped 13.5% after Q3 2026 EPS beat and raised full-year guidance. Hip segment grew 7% constant currency. Here's the trade setup.
Key Points
- Zimmer Biomet surged 13.5% on November 4 after Q3 adjusted EPS of $1.90 beat consensus by $0.02 and the company raised its full-year 2026 adjusted EPS guidance midpoint to $8.55 — just above analyst consensus of $8.54.
- Hip segment growth of 7.0% constant currency and Technology & Data/Bone Cement/Surgical expansion of 13.0% drove the beat, partially offset by a 2.6% decline in Knees.
- The Democratic congressional sweep created a simultaneous macro tailwind for managed care and procedure-volume-sensitive medical device names, amplifying what was already a clean fundamental catalyst.
Zimmer Biomet posted adjusted EPS of $1.90 on $2.06 billion in Q3 revenue, beat on both lines, raised full-year guidance, and watched its stock rocket 13.5% on November 4 to become the third-best performer in the S&P 500 for the session. The result — clean, specific, and accompanied by a credible guidance lift — landed in a market environment that was already aggressively buying healthcare exposure following a Democratic congressional sweep.
The Numbers Behind the Pop
Strip away the macro tailwind and ZBH's quarter still stands on its own. Q3 adjusted EPS of $1.90 cleared the $1.88 consensus by $0.02 — not a blowout, but in medical devices, consistency and guidance trajectory matter more than the size of the beat. Revenue at $2.06 billion topped the $2.04 billion estimate and represented 3.1% reported growth year-over-year, or 3.7% on a constant-currency basis, which is the number that matters for evaluating underlying procedure demand absent the noise of foreign exchange translation.
The segment breakdown tells a more nuanced story. Hips — the segment that most directly reflects elective procedure volume and an aging global population's demand for joint replacement — grew 7.0% on a constant currency basis. That is a strong print for a category that has been dealing with post-pandemic procedure normalization. Technology & Data, Bone Cement, and Surgical combined for 13.0% constant currency growth, a number that reflects both pricing power in higher-margin product lines and the company's ongoing push into digital surgery and enabling technologies. The weak spot was Knees, which declined 2.6% constant currency. That decline warrants monitoring — Knees is a large revenue contributor and consistent negative growth in that segment would eventually offset Hip and Technology strength — but for one quarter, in the context of an overall beat, the market appropriately looked through it.
Full-year 2026 organic constant currency revenue growth guidance was revised upward to 3.0%–3.5% from the prior range of 2.25%–3.25%, a meaningful upgrade at the midpoint. Adjusted EPS guidance moved to $8.50–$8.60, implying a midpoint of $8.55 — essentially sitting one penny above the analyst consensus of $8.54. That precision is deliberate. Management is signaling confidence without over-promising, which is exactly the credibility-preserving posture that institutions want to see from a medical device company whose valuation depends on predictable, compounding earnings delivery.
The Macro Amplifier
The 13.5% single-session gain is not entirely explained by fundamentals. A 2-cent EPS beat and a guidance raise to the midpoint of $8.55 is worth maybe 4–6% in a neutral tape for a company of ZBH's profile. The other 7–9 percentage points came from the November 4 political backdrop: a Democratic congressional sweep that investors immediately interpreted as favorable for managed care expansion, Affordable Care Act enrollment, and by extension, the volume of elective surgical procedures that drive Zimmer Biomet's top line.
The logic runs as follows: broader insurance coverage leads to more patients who can afford elective joint replacement surgery, which flows directly into ZBH's hip and knee revenue. It is a macro-to-micro translation that sophisticated healthcare investors make quickly, and on November 4 they made it decisively. The day's market action confirmed the rotation in full — Universal Health Services rose 10.9%, Centene gained 12.6%, and the broader healthcare complex was among the strongest sectors in an S&P 500 that advanced 1.6%.
For ZBH specifically, the ACA tailwind is real but its timeline is long. Policy changes take 12–24 months to show up meaningfully in procedure volumes. Investors buying ZBH on November 4 are making a bet that the political environment sustains and translates into incremental volume over the next two to four reporting cycles — not next quarter. That forward-looking premium is embedded in today's price, which means ZBH is now priced for continued execution without much room for a guidance miss or macro reversal.
What Traders Watch Next
The setup entering November 5 and beyond requires distinguishing between ZBH as a momentum trade and ZBH as a fundamental holding. As a momentum trade, the 13.5% gap means the stock needs a catalyst-free consolidation period to absorb the move before the next leg becomes achievable. Gap-and-go sessions of this magnitude on earnings — particularly in names that are not high-frequency trader favorites — often see profit-taking pressure in the 2–5 sessions following the initial pop, as short-term funds that bought the pre-earnings setup exit into the strength. The absence of any immediately visible new catalyst until the Q4 print — which will not arrive until early 2027 — creates a vacuum where selling can accelerate without a counter-narrative.
As a fundamental holding, the valuation question centers on where ZBH trades relative to its raised guidance midpoint of $8.55. At yesterday's pre-earnings close, ZBH was trading at a moderate discount to orthopedic device peers. At a 13.5% higher price — implying a close somewhere in the mid-to-high $60s depending on its pre-earnings level — the gap to peers has narrowed. ZBH would need the Knee segment to inflect positive and the Hip momentum to sustain at or above 5% constant currency growth to justify multiple expansion from current levels.
The specific level to watch is the full-year adjusted EPS guidance midpoint of $8.55 relative to any Q4 pre-announcement or January guidance update. If ZBH can demonstrate in Q4 that Hip growth is tracking at or above 7% and that Knees are stabilizing — even a return to flat constant currency would be meaningful — then the raised guidance range becomes a floor rather than a ceiling for 2027 consensus estimates. That is the scenario where November 4's 13.5% gain looks like the beginning of a re-rating rather than a one-day event. The first read on that thesis arrives with the Q4 2026 earnings release, expected in late January or early February 2027. Until then, $8.55 in full-year EPS is the number every ZBH holder should have pinned.
The Weekly Investor
Daily market analysis for active traders. Free.
